FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/06/069469 [Registered on: 25/06/2024] Trial Registered Prospectively
Last Modified On: 25/06/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Surgical/Anesthesia 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Giving medicine dexamethasone two times as compared to one time only to decrease pain and edema after major surgery of the abdomen. 
Scientific Title of Study   Effect of two dose versus single dose dexamethasone on pain and post-operative inflammatory response in patients undergoing major abdominal surgery: A double- blinded randomised controlled trial. 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Priyankar Kumar Datta 
Designation  Assistant Professor 
Affiliation  AIIMS, New Delhi 
Address  Dept of Anaesthesiology, Pain Medicine and Critical Care, 5th Floor, Academic Block, AIIMS, Ansari Nagar
Ansari Nagar
South
DELHI
110029
India 
Phone  01126593212  
Fax    
Email  priyankar.k.datta@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Ajisha Aravindan 
Designation  Associate Professor 
Affiliation  All India Institute of Medical Sciences 
Address  Dept of Anaesthesiology, Pain Medicine and Critical Care, 5th Floor, Academic Block, AIIMS, Ansari Nagar

South
DELHI
110029
India 
Phone  01126593212  
Fax    
Email  ajishaa@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Priyankar Kumar Datta 
Designation  Assistant Professor 
Affiliation  AIIMS, New Delhi 
Address  Dept of Anaesthesiology, Pain Medicine and Critical Care, 5th Floor, Academic Block, AIIMS, Ansari Nagar

South
DELHI
110029
India 
Phone  01126593212  
Fax    
Email  priyankar.k.datta@gmail.com  
 
Source of Monetary or Material Support  
AIIMS Delhi Early career intramural grant All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029 
 
Primary Sponsor  
Name  All India Institute of Medical Sciences 
Address  Ansari Nagar, New Delhi 110029 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
Nil  Nil 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Priyankar Kumar Datta  All India Institute of Medical Sciences  OT Complex, Department of Anaesthesiology,Pain medicine, and Critical Care, Ansari Nagar 110029
South
DELHI 
9830771756

priyankar.k.datta@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
AIIMS Institute Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: O||Medical and Surgical,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Single dose dexamethasone  First dose of dexamethasone 0.2 mg/kg IV infusion in 100 ml normal saline will be given immediately following induction of anaesthesia, and after 12 hours from first dose, infusion of 100 ml normal saline will be given as placebo. 
Intervention  Two dose dexamethasone  First dose of dexamethasone 0.2 mg/kg IV infusion in 100 ml normal saline will be given immediately following induction of anaesthesia, and second dose 0.2 mg/kg IV in 100 ml normal saline will be given 12 hours after the first dose. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  Adult patients of ASA physical status I and II scheduled for elective major open abdominal surgery 
 
ExclusionCriteria 
Details  Diabetic
COPD or asthma
History of peptic ulcer disease
Current or recent steroid intake within last 4 weeks
Any concurrent infection
BMI more than 35
Pregnancy and lactation 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant and Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
a)mean post-operative CRP level
b)mean post-operative VAS score (by asking patients to grade the worst pain experienced by them during the preceding 12 hours)
 
a)postoperative days 1 and 3 and 5
b)recorded twice daily at 8-9 am and 8-9 pm up to postoperative day 5  
 
Secondary Outcome  
Outcome  TimePoints 
mean post-operative IL6 level
 
measured on POD1, 3 & 5
 
mean SOFA score  recorded daily for the first 7 post-operative days 
duration of ICU stay, duration of hospital stay  recorded daily for the first 7 post-operative days 
d) incidence of postoperative nausea and vomiting (PONV) and the additional use of postoperative antiemetics  recorded daily for the first 7 post-operative days 
need for rescue analgesics  recorded daily for the first 7 post-operative days 
incidence of prolonged post-operative ileus, defined as meeting 2 or more of the following criteria on or after postoperative day (POD) 4: (1) nausea or vomiting, (2) inability to tolerate an oral diet over the last 24 hours, (3) abdominal distension, and (4) radiologic confirmation.  recorded daily for the first 7 post-operative days 
g) time to GI-2 recovery – defined as time to the later of upper (first tolerance of solid food) and lower (first bowel movement) gastrointestinal recovery (for patients with a stoma creation, first bowel movement was defined as more than 50–100 mL of bowel contents in the stoma bag after surgery)  recorded daily for the first 7 post-operative days 
incidence of surgical site infection prior to hospital discharge  recorded daily for the first 7 post-operative days 
incidence of GI bleed before hospital discharge  recorded daily for the first 7 post-operative days 
major postoperative complications (defined as Clavien-Dindo grade 3-4)  recorded daily for the first 7 post-operative days 
 
Target Sample Size   Total Sample Size="130"
Sample Size from India="130" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   01/08/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - All of the individual participant data collected during the trial, after de-identification.

  2. What additional supporting information will be shared?
    Response -  Study Protocol

  3. Who will be able to view these files?
    Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.

  4. For what types of analyses will this data be available?
    Response - To achieve aims in the approved proposal.

  5. By what mechanism will data be made available?
    Response - Proposals should be directed to [priyankar.k.datta@gmail.com].

  6. For how long will this data be available start date provided 01-06-2028 and end date provided 01-06-2038?
    Response - Immediately following publication. No end date.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary  

Effect of two dose versus single dose dexamethasone on pain and post-operative inflammatory response in patients undergoing major abdominal surgery: A double- blinded randomised controlled trial.

 

BACKGROUND

Excessive post-operative inflammatory response may lead to post-operative systemic inflammatory dysregulation – a state of dysregulated host response to surgical injury, in which progression to SIRS and infectious complications is more likely.1 Therefore, attenuation of the post-operative inflammatory response may help reduce post-operative morbidity and mortality. Evidence suggests that dexamethasone, through its anti-inflammatory action, reduces post-operative ileus and enhances functional gut recovery after major bowel surgery.2 The role of dexamethasone is reducing post-operative pain and nausea vomiting is well established.3,4

 Dexamethasone has a long biological half-life of approximately 36-54 hours.5 However, as post-operative inflammatory response usually peaks on the third post-operative day,2 a single dose of dexamethasone at induction of anaesthesia, as is the current practice, may not be adequate for effectively suppressing post-operative inflammation.

 

We hypothesize that two doses of dexamethasone, one administered at the induction of anaesthesia, followed by a second dose 12 hours after the initial dose, will be more effective in attenuating the post-operative inflammatory response, pain, and functional gastrointestinal recovery, compared to a single dose of dexamethasone at anaesthesia induction, without increasing adverse effects.


METHODS

After obtaining informed written consent, patients will be randomly allocated into:

·       Group 1: Single dose dexamethasone (0.2 mg/kg immediately following induction)

·       Group 2: Two-dose dexamethasone (0.2 mg/kg immediately following induction, and second dose 12 hours after the initial dose)

Intravenous access will be secured, and baseline blood sample (5 ml) will be obtained prior to induction. Further blood samples (5 ml each) will be obtained on post-operative day 1, 3 and 5.

Standard technique of anaesthesia for major abdominal laparotomies will be followed. All patients will receive general anaesthesia along with thoracic epidural infusion of local anaesthetic during the intra-operative period. Post-operative analgesia will be maintained with epidural morphine 50 mcg/kg every 12 hours for 48 hours along with IV paracetamol (15mg/kg every 6 hours). IV tramadol (1mg/kg) will be used for rescue analgesia. All patients will receive post-operative nausea and vomiting (PONV) prophylaxis with IV ondansetron 0.1 mg/kg at the end of surgery.

Blood sugar will be monitored every 2 hours during the intra-operative period and every 6 hours in the post-operative period for 48 hours. Hyperglycemia (BS > 180 g/dl) will be treated with insulin infusion. All patients will receive peri-operative stress ulcer prophylaxis with pantoprazole 40 mg IV once daily.

 

The schedule of the intervention drug or placebo will be as follows:

 

Group 1

Group 2

At anaesthesia induction

IV infusion of 0.2 mg/kg dexamethasone in 100 ml of normal saline

12-hours after initial dose

IV infusion of 100 ml of normal saline (PLACEBO)

IV infusion of 0.2 mg/kg dexamethasone in 100 ml of normal saline

 

Sample size calculation:

Minimum required sample size has been calculated separately for each primary outcome. Sample size for CRP level is based on a two-sided T-test model with an expected mean (± SD) post-operative CRP level in single dose dexamethasone group as 125 (± 50) mg/L,6 and a 25% reduction in CRP level considered clinically significant. With an alpha error of 0.05 and power of study at 80%, the required minimum sample size is 41 in each group.

Sample size for mean VAS score has been calculated based on a two-sided T-test model with an expected mean (± SD) post-operative VAS score in single dose dexamethasone group as 3 (± 2),2 and a reduction in VAS score by 1 considered clinically significant. With an alpha error of 0.05 and power of study at 80%, the required minimum sample size is 63 in each group.

Therefore, it has been decided to recruit a total of 130 patient in the study.

 

Statistical analysis:

Quantitative data will be assessed using Mann-Whitney U-test or student’s t-test, and qualitative data will be assessed using chi-square test or Fischer’s exact test. A p value of less than 0.05 will be considered statistically significant.

 

REFERENCES

1. Bain CR, Myles PS, Corcoran T, Dieleman JM. Postoperative systemic inflammatory dysregulation and corticosteroids: a narrative review. Anaesthesia. 2023;78(3):356-370. doi:10.1111/anae.15896

2. Zhang T, Xu Y, Yao Y, et al. Randomized Controlled Trial: Perioperative Dexamethasone Reduces Excessive Postoperative Inflammatory Response and Ileus After Surgery for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021;27(11):1756-1765. doi:10.1093/ibd/izab065

3. De Oliveira GS, Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2011;115(3):575-588. doi:10.1097/ALN.0b013e31822a24c2

4. Waldron NH, Jones CA, Gan TJ, Allen TK, Habib AS. Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis. Br J Anaesth. 2013;110(2):191-200. doi:10.1093/bja/aes431

5. Drug vignettes: Dexamethasone. The Centre for Evidence-Based Medicine. Accessed April 29, 2023. https://www.cebm.net/covid-19/dexamethasone/

6. Straatman J, Cuesta MA, Tuynman JB, Veenhof AAFA, Bemelman WA, van der Peet DL. C-reactive protein in predicting major postoperative complications are there differences in open and minimally invasive colorectal surgery? Substudy from a randomized clinical trial. Surg Endosc. 2018;32(6):2877-2885. doi:10.1007/s00464-017-5996-9

 

 

 

 
Close